title: Combined treatment with GH, insulin, and indomethacin alleviates cancer cachexia in a mouse model.
abstract: Cancer-induced cachexia involves weight loss, catabolic activity, and inflammation. We have evaluated the effects of various treatments (GH, insulin (INS), indomethacin (IND), and all possible combinations) on cancer cachexia in a mouse model. BALB/c mice that were implanted with colon-26 adenocarcinoma developed cachexia in 9 days. Body weight, tumor volume, tumor-free weight, inflammatory cytokines (tumor necrosis factor-α (TNF-α), interleukin 6 (IL6)), and nutritional markers (glucose (Glu), albumin, triglycerides (TGs)) of treatment and control groups were monitored. In the cachexia group, there was a significant decrease in tumor-free bodyweight by day 11. Treatment with GH+INS+IND significantly alleviated tumor-free bodyweight reduction and cachexia-induced changes in nutritional markers and cytokines, and prolonged survival time. GH+INS+IND treatment was more effective than other treatment combinations in elevating Glu and TGs, reducing TNF-α and IL6 levels, and prolonging survival time. In conclusion, GH+INS+IND alleviated cachexia symptoms in a murine model of cancer cachexia.
authors.affiliation: Department of Gastrointestinal Surgery, The First Affiliated Hospital, Fujian Medical University, No. 20, Chating Zhong Road, Fuzhou, Fujian 350005, People's Republic of China. chensz04871@hotmail.com
authors.forename: Si-Zeng
authors.initials: SZ
authors.lastname: Chen
authors.forename: Zheng-Guo
authors.initials: ZG
authors.lastname: Qiu
mesh_terms: D000230:Adenocarcinoma / Q000150:complications* / Q000473:pathology; D000818:Animals; D015415:Biomarkers / Q000097:blood; D001835:Body Weight / Q000187:drug effects; D002100:Cachexia / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality / Q000503:physiopathology; D003110:Colonic Neoplasms / Q000150:complications* / Q000473:pathology; D016207:Cytokines / Q000097:blood; D004338:Drug Combinations; D013006:Growth Hormone / Q000008:administration & dosage*; D007213:Indomethacin / Q000008:administration & dosage*; D007274:Injections, Intraperitoneal; D007328:Insulin / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009747:Nutritional Physiological Phenomena; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D016207:Cytokines; D004338:Drug Combinations; D007328:Insulin; D013006:Growth Hormone; D007213:Indomethacin